Register entry
BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 12
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
12| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 6967208 | ELIQUISapixaban | substance, product | Nov 2026 |
| 6967208*PED | ELIQUISapixaban | use | May 2027 |
| 9326945 | ELIQUISapixaban | product | Feb 2031 |
| 9326945*PED | ELIQUISapixaban | use | Aug 2031 |
| Product | Exclusivity | Until |
|---|---|---|
| ELIQUISAPIXABAN | PED Paediatric | Oct 2028 |
Enquiry
Common questions
- Is BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE FDA approved?
- BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.